Stoke Therapeutics, Inc. (NASDAQ:STOK) Expected to Earn Q1 2025 Earnings of ($0.59) Per Share

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Investment analysts at Wedbush issued their Q1 2025 earnings per share estimates for shares of Stoke Therapeutics in a report issued on Wednesday, August 7th. Wedbush analyst L. Chico forecasts that the company will post earnings of ($0.59) per share for the quarter. Wedbush has a “Outperform” rating and a $17.00 price objective on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.37) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.63) EPS and Q4 2025 earnings at ($0.59) EPS.

A number of other research firms also recently issued reports on STOK. HC Wainwright reiterated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, May 7th. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Thursday. Finally, Canaccord Genuity Group reduced their price target on shares of Stoke Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, May 7th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $21.40.

Stoke Therapeutics Price Performance

Shares of STOK stock traded up $0.28 during midday trading on Thursday, reaching $14.42. 289,051 shares of the company traded hands, compared to its average volume of 856,720. The firm’s 50 day simple moving average is $14.47 and its two-hundred day simple moving average is $11.23. Stoke Therapeutics has a 1-year low of $3.35 and a 1-year high of $17.58. The firm has a market cap of $751.57 million, a PE ratio of -5.98 and a beta of 0.87.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.11. The company had revenue of $4.83 million for the quarter, compared to analyst estimates of $3.33 million.

Insider Buying and Selling

In related news, insider Barry Ticho sold 10,000 shares of Stoke Therapeutics stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $13.75, for a total transaction of $137,500.00. Following the completion of the transaction, the insider now directly owns 2,485 shares in the company, valued at approximately $34,168.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 11.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Quest Partners LLC purchased a new position in shares of Stoke Therapeutics during the 2nd quarter worth $29,000. Nisa Investment Advisors LLC lifted its stake in shares of Stoke Therapeutics by 53.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after purchasing an additional 1,038 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Stoke Therapeutics during the 2nd quarter worth $123,000. State Board of Administration of Florida Retirement System purchased a new position in shares of Stoke Therapeutics during the 1st quarter worth $141,000. Finally, BNP Paribas Financial Markets lifted its stake in shares of Stoke Therapeutics by 86.2% during the 1st quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock worth $193,000 after purchasing an additional 6,636 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.